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Abstract
Articular cartilage and the underlying subchondral bone are crucial in human movement and when damaged through disease 
or trauma impacts severely on quality of life. Cartilage has a limited regenerative capacity due to its avascular composition 
and current therapeutic interventions have limited efficacy. With a rapidly ageing population globally, the numbers of patients 
requiring therapy for osteochondral disorders is rising, leading to increasing pressures on healthcare systems. Research 
into novel therapies using tissue engineering has become a priority. However, rational design of biomimetic and clinically 
effective tissue constructs requires basic understanding of osteochondral biological composition, structure, and mechanical 
properties. Furthermore, consideration of material design, scaffold architecture, and biofabrication strategies, is needed to 
assist in the development of tissue engineering therapies enabling successful translation into the clinical arena. This review 
provides a starting point for any researcher investigating tissue engineering for osteochondral applications. An overview of 
biological properties of osteochondral tissue, current clinical practices, the role of tissue engineering and biofabrication, 
and key challenges associated with new treatments is provided. Developing precisely engineered tissue constructs with 
mechanical and phenotypic stability is the goal. Future work should focus on multi-stimulatory environments, long-term 
studies to determine phenotypic alterations and tissue formation, and the development of novel bioreactor systems that can 
more accurately resemble the in vivo environment.
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Introduction
Osteochondral tissue is composed of articular cartilage, a 
specialised tissue that covers the distal ends of the bones in 
articulating joints, and the subchondral bone which anchors 
the cartilage to the underlying bone [1–5]. Articular cartilage 
has a highly flexible and lubricated surface to reduce fric-
tional forces during movement and facilitate smooth articu-
lation. The tissue enables the transmission of mechanical 
loads from movement to the skeleton [6–9]. Osteochondral 
tissue is composed of distinct regions with articular carti-
lage, comprising the majority of the structure, and an under-
lying subchondral bone phase.
Articular cartilage is avascular and aneural with low 
metabolic activity and thus when trauma or disease (e.g. 
osteoarthritis and rheumatoid arthritis) affects the tissue 
significant issues arise, which are difficult to treat due to 
the inherent inability of articular cartilage to self-regener-
ate in comparison to the greater healing capacity of bone 
(Fig. 1). As an avascular tissue, cartilage lacks ready access 
to a supply of circulating stem cells and nutrients thus relies 
on the synovial fluid for nourishment. This combined with 
its largely acellular composition and low metabolic activ-
ity results in a nearly complete lack of innate regenerative 
capacity. Consequentially, defects due to disease and trauma 
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fail to heal, and clinical interventions typically result in the 
formation of fibrocartilage which has reduced functional-
ity. In contrast, bone has a greater ability for self-repair due 
to constant tissue remodelling by the dynamic interplay 
between osteoblasts and osteoclasts. Bone is also a highly 
vascularised tissue which allows a ready supply of nutrients 
and proteins that stimulate bone repair. Furthermore, there 
is a large source of stem cells in the bone marrow and peri-
osteum which can differentiate into osteoblasts. This allows 
bone to heal defects up to a certain critical size after which 
vascularisation becomes an issue. A thorough understanding 
of the composition and structure of the tissue will enable 
superior tissue engineering approaches to be explored to 
solve the clinical challenges of osteochondral defects.
Current clinical approaches, typically palliative, are inef-
fective at the early stages of tissue degradation and the tissue 
either continues to degrade, resulting in total replacement 
with an implant, or leads to the formation of fibrocartilage. 
Regenerative medicine and tissue engineering approaches 
have been widely explored to develop new approaches 
to repair and regenerate osteochondral tissue [7, 9–13]. 
These approaches often involve a combination of bioma-
terials, cells, scaffolds (temporary structures that allow cell 
attachment and tissue growth), and/or biomolecules (e.g. 
growth factors, cytokines, hormones, and nucleic acids) to 
develop a range of strategies for the repair, replacement, and 
regeneration of damaged tissues and organs. These strate-
gies typically aim to mimic the biochemical and biophysi-
cal environment of the extracellular matrix (ECM) of the 
target tissue to promote a desirable cell response. Thus, the 
design and engineering of functional biomaterials and incor-
poration of bioactive molecules plays a major role in the 
development of clinically effective tissue engineering strate-
gies. A key contributing factor to the success of these strat-
egies rely on the fabrication technique utilised to generate 
the scaffolds which can be produced through conventional 
(e.g. electrospinning, solvent casting, particulate-leaching, 
gas foaming, and freeze drying) and additive manufacturing 
techniques (e.g. material extrusion, stereolithography, inkjet, 
and powder-bed fusion) [14, 15]. While conventional tech-
niques and 3D printing technologies enable the fabrication 
of 3D scaffolds amenable to cell seeding, 3D bioprinting 
technologies afford the fabrication of 3D constructs through 
the simultaneous positioning of biomaterials and living cells 
in a prescribed layer-by-layer organisation The scaffold mor-
phological parameters such as porosity, interconnectivity, 
Fig. 1  Comparison between the physiology and healing capacity of bone and cartilage. Image from [9]
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and fibre diameter have a critical role in regulating cellular 
growth and behaviour, hence, the use of additive manufac-
turing technologies enables precise fabrication of complex 
structures that are not possible through conventional meth-
ods. A decisive development within tissue engineering is the 
advancement of three-dimensional (3D) bioprinting which 
offers a paradigm shift in the fabrication of complex multi-
material structures containing biomaterials, cells, and bio-
molecules [14, 16, 17].
However, to date existing tissue engineering strategies 
have been unsuccessful in producing functional and mature 
articular cartilage. The fundamental tissue engineering 
approaches may need to be revaluated to understand why 
these approaches consistently fail in producing a relatively 
simple and thin tissue, although exhibiting a highly com-
plex hierarchical organisation [18]. Adult articular cartilage 
takes over 20 years to mature and once formed the tissue 
does not turnover or regenerate unlike other tissues in the 
body. The tissue produced during childhood is the same 
throughout a person’s lifetime. Malda et al. [18] suggest that 
new approaches must appreciate this fundamental aspect of 
cartilage tissue physiology which may potentially require 
the incorporation of constructs with precisely controllable 
degradation rates to match the exceptionally low remod-
elling of native cartilage ECM. These authors argue that 
biomechanical cues in addition to restoring the biochemi-
cal and biophysical microenvironment at the early stages 
of development (fetal and childhood) is essential to support 
the recapitulation of developmental processes underlying 
the restoration and formation of articular cartilage tissue. 
Furthermore, elucidating the underlying processes of carti-
lage development will provide a mechanistic understanding 
that will inform the rational design of tissue engineering 
approaches for cartilage regeneration.
This paper provides an overview of the structure, com-
position, and biomechanics of osteochondral tissue, along 
with currently available clinical treatments. We will then 
discuss the requirements and challenges in tissue engineer-
ing regarding suitable materials, biological factors, cellu-
lar and acellular scaffolds, the utilisation of 3D bioprinting 
technologies, and in vitro maturation techniques to provide 
a starting point for new researchers in the field. Finally, we 
highlight clinical developments and regulatory hurdles that 
should be considered during the research stage as well as the 
challenges still to overcome within the field.
Osteochondral tissue
There are three forms of cartilage in the human body includ-
ing fibrocartilage [19], elastic cartilage, and hyaline carti-
lage each with their own specific biological, mechanical, and 
structural properties [20]. Hyaline cartilage is a thin tissue 
present at synovial joints such as the knee, elbow, shoulder, 
and hip where it covers the bearing surface of the underly-
ing bone and is termed articular cartilage [21]. Articular 
cartilage is anchored to the subchondral bone and forms the 
osteochondral unit. Hyaline cartilage provides an efficient 
load bearing surface that has a low friction coefficient thus 
lubricating the movement of joints and can support load 
transfer of up to six times the human body weight in the 
knees [6]. The complex, nonlinear, viscoelastic, anisotropic, 
and heterogeneous structure and composition of cartilage 
enable these vital properties [22, 23].
Composition of articular cartilage
Adult articular cartilage consists of predominately ECM, 
approximately 95–99% of the total volume, which itself con-
sists of 80% water and 20% solid contents [24]. The solid 
content is mostly comprised of collagens (50–75%), pro-
teoglycans (15–30%), and a small amount of non-collagen 
proteins [21, 25]. Cells account for a small percentage of the 
total volume (1–5%) and consist of only a single cell type, 
chondrocytes [26]. The composition of articular cartilage 
changes as the tissue matures from initial formation during 
embryogenesis to final maturation (18–21 years old) [27].
The mature tissue has a low density of chondrocytes in 
a low proliferative and metabolic state, which are isolated 
from each other within the pericellular matrix and, there-
fore, lack cell–cell interactions [8]. This is partly responsible 
for the low healing capacity of mature articular cartilage. 
However, mature chondrocytes have an important role in the 
tissue homeostasis by coordinating and producing the ECM 
components. The morphology, orientation, and phenotypic 
expression of chondrocytes are depth and biomechanically 
dependent as the cells are influenced through mechanotrans-
duction [28, 29]. This results in the wide range of morpholo-
gies observed, which range from rounded, elongated, flat-
tened, and hypertrophic, all within the same tissue [30].
The collagen network in articular cartilage is highly 
organised and primarily composed of collagen type II 
(~ 50% dry weight of articular cartilage) [22]. It is assem-
bled through procollagen polypeptides binding together to 
form collagen that assembles into micro-fibrils and then 
fibrils which can be cross-linked together by collagen type 
IX [31–33]. These collagen fibrils exhibit a characteristic 
banding pattern of ~ 67 nm due to the staggered packing 
arrangement of collagen (Fig. 2a). The organisation is 
depth dependent in the tissue and is partly responsible 
for the biomechanics, especially the tensile and com-
pressive properties [23]. The fibre diameter increases 
from the articular surface through the depth of the tissue 
(superficial zone ~ 55 nm, middle zone ~ 87 nm, and deep 
zone ~ 108 nm) [34]. Although collagen type II is the main 
collagen (95% of total collagen), there are other collagens 
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present such as type I, II, VI, IX, X, and XI. Collagen type 
I is present in small amounts only in the superficial zone, 
but can be found abundantly in fibrocartilage so can be 
used as a useful indicator of fibrocartilage formation [33, 
35, 36]. Subsequently, the ratio between collagen I and 
collagen II can be used as a marker to assess the status 
of the cartilage tissue as chondrocytes cultured in vitro 
monolayer express higher levels of collagen type I indicat-
ing that the chondrocytes have undergone dedifferentiation 
[29]. Collagen IX and XI are found throughout the tissue 
in small amounts and are involved in crosslinking between 
fibrils, regulation of fibril size, and interactions with other 
biomolecules [22]. Collagen X is found in the deep and 
calcified zones and is believed to have a role in the miner-
alisation between the cartilage and the subchondral bone 
[37, 38]. A major non-collagenous component of the ECM 
are proteoglycans and glycosaminoglycan’s (GAGs) [6]. 
Proteoglycans consist of a core protein that is heavily 
bound with covalently attached polysaccharide chains, 
GAGs. Aggrecan is a main proteoglycan within articular 
cartilage and is covalently attached to negatively charged 
GAGs, keratan sulphate and chondroitin sulphate. This is 
able to bind multiple times to a hyaluronic acid backbone 
to form aggrecan-hyaluronan aggregates which are highly 
negatively charged [39, 40]. The negative charge on this 
proteoglycan aggregate, and other proteoglycans, causes 
an osmotic pressure to be generated as water is taken in 
and entrapped which causes swelling [37]. This turgid-
ity produced by the network of proteoglycans combined 
with the structural confinement caused by the organisa-
tion of collagen results in a high compressive modulus 
[3, 29]. Subsequently, as the concentration of proteogly-
cans increases with depth in articular cartilage towards the 
subchondral bone region, the water content and swelling 
pressure rises, thus the compressive modulus of the tissue 
increases [12, 41–43]. This enables articular cartilage to 
have a high mechanical load bearing capability which can 
transfer and distribute loads effectively [43].
Fig. 2  Hierarchical and graded composition, structure, and properties 
of osteochondral tissue. a Collagen fibril assembly. Image from ref-
erence [33]. b Molecular composition and arrangement of the chon-
dron depicting the pericellular, territorial, and interterritorial matrix 
with increasing distance from the chondrocyte. Image from reference 
[36]. c Zonal structure and properties of osteochondral tissue. Image 
adapted from [50]
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Structure of osteochondral tissue
Articular cartilage has a hierarchical organisation from the 
nanoscale to the macroscale with a distinct zonal structure. 
Each zone has its own specific ECM composition, biomol-
ecule orientation, chondrocyte shape and organisation [44], 
imparting specific biomechanical characteristics (Fig. 2c). 
These zones are termed, descending from the articulating 
surface, the superficial or tangential zone, the middle or 
transitional zone, the deep or radial zone, and the calcified 
zone, before the articular cartilage gives way to the sub-
chondral bone region. Furthermore, there is a microscale 
radial organisation surrounding the chondrocyte termed the 
chondron which has a unique composition depending on the 
distance from the chondrocyte (Fig. 2b).
On the articular surface and above the superficial zone 
is a thin layer, ranging from a few hundred nanometres to a 
micrometre, termed the lamina splendens which is acellular 
and composed of proteins [45]. Although the lamina splen-
dens role is unclear it is thought that the gradual build-up 
of proteins from the synovial fluid acts as a protective and 
low friction interface for the articular cartilage surface [35].
Immediately below the lamina splendens is the superfi-
cial zone (10–20% of cartilage thickness), which comprises 
small diameter collagen fibres (predominately type II and 
IX) that are organised parallel to the articular surface and 
densely packed. This allows a low coefficient of friction, 
which enables smooth movement of the joint and imparts the 
ability to withstand both the high tensile and shear stresses 
that the articular cartilage encounters under loading. The 
chondrocytes are densely packed and arrange themselves 
along the collagen fibres parallel to the surface, displaying 
a flattened morphology. Chondrocytes also secrete pro-
teins such as superficial zone protein (SPZ, also known as 
lubricin or PGR 4) and collagen I which act as lubricants 
[22, 46–48]. SPZ is a potential marker to identify this zone. 
The amount of proteoglycans is low compared to the other 
zones which increases the permeability, thus resulting in 
compressive strains of up to 50% and high fluid flow which 
influences the compressive properties of the entire cartilage 
tissue [22, 23, 39, 49].
Below the superficial zone is the middle zone (40–60% 
of cartilage thickness), which is predominately composed 
of collagen II fibres randomly arranged and displaying a 
larger diameter than the superficial zone. Chondrocytes are 
present at a lower density, display a rounded morphology, 
and express large quantities of collagen II and aggrecan. 
A marker for this zone is the cartilage intermediate layer 
protein which is expressed throughout this zone [38]. This 
zone also has the highest concentration of proteoglycans 
especially aggrecan [49, 51].
The deep zone (20–50% of cartilage thickness) is com-
prised of the largest diameter collagen fibres that are 
oriented perpendicular to the subchondral bone region with 
the chondrocytes organised along the collagen fibres in col-
umns with an elongated morphology. The cells themselves 
are present in lower density compared to the other zones and 
express lower levels of collagen II [51, 52].
The final zone before the subchondral bone region is the 
calcified zone which is distinguished from the deep zone 
by the presence of a tidemark which demarks the boundary 
between calcified and non-calcified regions [53, 54]. The 
zone anchors the collagen fibres of the deep zone to the sub-
chondral bone thus integrating the cartilage to the underlying 
bone. This also provides an interface between the hard phase 
of bone and the soft phase of cartilage since the presence of 
hydroxyapatite reduces the mechanical gradient between the 
phases [22, 40, 55]. The calcified zone also has the highest 
number of chondrocytes which are in a hypertrophic state.
The final zone of the osteochondral tissue is the subchon-
dral bone which lies directly below the calcified zone and 
separates the articular cartilage from the bone marrow. This 
zone consists of the bony lamella (cortical endplate) and 
the subarticular spongiosa (supporting trabeculae and bone 
components), which is separated from the calcified zone of 
articular cartilage by a cement line [1, 56, 57]. The sub-
chondral bone differs markedly in composition and struc-
ture to the articular cartilage. The subchondral trabeculae 
are highly vascularised which acts as a nutrient source for 
articular cartilage enabling transportation of nutrients, gases, 
and waste through channels that cross the subchondral bone 
plate and enter the calcified zone, apart from these channels 
the tissue is entirely reliant on the surrounding synovial fluid 
as a source of nutrients [42, 56, 57]. The main collagen is 
type I due to the tissue being mineralised bone. These col-
lagen fibres do not cross between the calcified cartilage and 
subchondral bone region, so it does not act as an anchor as 
occurs with collagen fibres that cross the tidemark and con-
nect the non-calcified and calcified cartilage. Furthermore, 
the subchondral trabecular structure and mechanical proper-
ties are anisotropic and the subchondral bone can dynami-
cally remodel itself to respond to applied forces [58–60]. 
The main function of the subchondral bone is to maintain 
joint shape and provide mechanical support since it has a 
high compressive modulus and is impermeable, so is able 
to stabilise the tissue and distribute the applied mechanical 
forces [22, 39, 56, 61, 62].
Current osteochondral treatments
The zonal structure of osteochondral tissue and the innate 
inability of articular cartilage for self-regeneration poses a 
problem for clinical interventions. Hence, there are a vari-
ety of clinical treatments available which bring with them 
different degrees of success as well as tissue engineering 
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approaches which are predominantly in clinical trial phases 
rather than in mainstream use in clinical practice [10, 
63–66].
The main treatment strategies currently used worldwide 
are classified into (1) microfracture, (2) autologous chondro-
cyte implantation, (3) matrix-induced autologous chondro-
cyte implantation, (4) osteochondral auto- and allo-grafts, 
(5) autologous matrix-induced chondrogenesis, and (6) bone 
marrow aspirate concentrate (Fig. 3) [7, 12, 13].
The type of treatment used will depend on the defect 
category, stage, size, and location. Osteochondral defects 
are commonly classified by the Outerbridge classification 
system which indicates the severity of a lesion. This sys-
tem classifies defects from grade I–IV, where a grade O 
defect is normal healthy articular cartilage (Fig. 4a); grade 
I indicates swelling and softening of the tissue; grade II 
indicates a partial thickness defect with a diameter less 
than 1.5 cm; grade III defect has a diameter greater than 
1.5 cm and presents as a full thickness lesion up to the 
subchondral bone; and grade IV is a full thickness defect 
that exposes the subchondral bone.
Patients with clinical conditions causing cartilage loss 
present either discrete cartilage loss in a joint surface or 
full thickness cartilage degeneration (Fig. 4b, c) [67]. Dis-
crete areas of cartilage loss, e.g. osteochondritis dissecans, 
often caused by trauma, affects the younger population, 
whereas full thickness cartilage loss in the whole joint 
affects more elderly patients and is as a result of a systemic 
disease such as rheumatoid arthritis or osteoarthritis [66, 
68, 69].
When considering discrete small areas of cartilage 
loss, patients present with pain due to exposed bone and 
Fig. 3  Current treatment options for cartilage regeneration. a A full-
thickness chondral lesion (Grade III). b The defect is debrided to 
remove damaged cartilage and bone to create a healthy border which 
enables improved tissue integration. c Microfracture drills into the 
subchondral bone to create channels that allow a blood clot to form in 
the defect. d Autologous chondrocyte implantation uses chondrocytes 
which are inserted into the defect and covered with a periosteal patch 
or a collagen membrane. e Matrix-induced autologous chondrocyte 
implantation, chondrocytes are cultured in vitro and seeded onto an 
absorbable 3D scaffold, then implanted into the defect, and fixed to 
the defect with fibrin glue. Image from [12]
Fig. 4  a Normal healthy cartilage, b discrete cartilage defect, c full thickness area of cartilage loss, d end stage arthritis, and e fibrocartilage 
formed next to hyaline cartilage after microfracture surgery
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mechanical symptoms (e.g. joint locking), due to the disrup-
tion in the smooth low friction joint surface.
Current solutions have failed in restoring hyaline cartilage 
surfaces of the joint [70]. The most common surgical proce-
dure to address small areas of cartilage loss is arthroscopic 
(keyhole) surgery, called debridement, which uses mechani-
cal shavers to remove debris from the joint and loose car-
tilage material, solving some of the mechanical symptoms 
[71]. The aim of the surgery is to remove all loose mate-
rial and roughen the surface of the exposed bone enough to 
allow new tissue to adhere and form in the base.
Due to the unpredictable results from debridement, alter-
native techniques have been developed to enhance biological 
healing in the cartilage defect with a variety used worldwide. 
The microfracture technique, popularised by Steadman since 
the 1980s [72, 73], involves the defect area being debrided 
to ensure a clean and stable margin before making 3 mm 
perforations in the subchondral bone, ensuring that the struc-
tural integrity of that bone is not compromised. This induces 
bleeding and allows a blood and bone marrow super clot to 
form in the above space creating an environment for multi-
potent marrow cells such as mesenchymal stem cells (MSCs) 
to differentiate and form a stable tissue. This super clot 
subsequently remodels into fibrocartilaginous tissue over a 
period of 12–16 months and requires a lengthy postopera-
tive rehabilitation period with limited mechanical loading 
[48, 74]. In one study, biopsies after microfracture treatment 
noted that 11% had formed predominantly hyaline cartilage 
and 17% a mixture of fibrocartilage and hyaline cartilage 
within them. The remaining patients formed either predomi-
nantly fibrocartilage or no tissue at all (Fig. 4e) [75, 76].
Although considered the gold standard by the FDA and 
some clinicians, the long-term outcomes for joint func-
tionality using microfracture technique has shown limited 
improvement [46, 47]. This is due to the inferior biome-
chanical and biochemical properties of fibrocartilage com-
pared to hyaline cartilage, which creates a mismatch between 
the native tissue and the neotissue [49, 77]. The treatment 
provides a short-term benefit to the patient but only post-
pones cartilage degeneration as the repair tissue typically 
deteriorates approximately 18–24 months after surgery [49]. 
Subsequently, five years after surgery the likelihood of treat-
ment failure is high irrespective of the cartilage defect [46, 
47]. This technique can also be combined with other treat-
ment methods and an advancement on the technique utilises 
a collagen matrix that is inserted into the defect to promote 
MSC differentiation into chondrocytes [51].
With continued poor results from microfracture due to 
a lack of differentiation of new tissue, further treatment 
options have been developed, such as the use of bulk osteo-
chondral auto- and allografts, or a procedure termed mosai-
cplasty, which involves the transplantation of osteochondral 
tissue from either the patient (autograft) or a tissue donor 
(allograft) [59]. Mosaicplasty involves taking a small osteo-
chondral plug/biopsy from the periphery of weight bearing 
joints, for example, the margins of the femoral condyles in 
the knee (non-loading or minimal loading region). This is 
then transplanted into the defect, which has been prepared 
with only healthy tissue remaining, and the graft is subse-
quently aligned with the native tissue. Mosaicplasty has been 
shown to have better results than microfracture, though there 
are a number of limitations to the technique [46, 60, 61]. The 
use of autografts is limited due to the need to restrict donor 
site morbidity which results in only small defect sizes (< 4 
 cm2) being treated and the lack of integration of the periph-
ery of the plugs with each other or the native hyaline carti-
lage [78]. Furthermore, the use of allografts (osteochondral 
material from a deceased donor) raises the potential issue 
of disease transmission and immunogenicity, however, the 
size of defect treated can be larger as the tissue is derived 
from cadavers. Finally, and most importantly when compar-
ing this against other treatment modalities, graft failure has 
been observed in up to 55% of patients after 10 years due to 
poor integration with the host tissue, often a major limita-
tion with other techniques as well, and degradation of the 
allograft [62].
Autologous chondrocyte implantation (ACI) techniques 
have been in use since the first reported series in 1987, 
which was developed as an improvement on the micro-
fracture technique [7, 12, 52, 53, 79]. The technique is a 
two-stage surgical procedure that first involves harvesting 
autologous chondrocytes using an arthroscopic (keyhole) 
technique from a minimal load bearing region through a 
biopsy punch and expanding these cells in vitro to obtain 
a population of approximately 12–48 million cells. In the 
second surgery, performed using an open approach rather 
than arthroscopic, the defect area is debrided, and the cell 
suspension is seeded into the defect area and confined to 
the defect by membrane coverage. The membrane used is 
typically a periosteal patch, however a major cause of treat-
ment failure is hypertrophy of the patch which can give rise 
to mechanical symptoms and aching similar to the original 
problem [54]. Subsequently, synthetic collagen or hyaluronic 
acid patches have been utilised, showing reduced failure 
rates (5–26%) due to patch hypertrophy [55]. However, these 
synthetic patches are considered as off-label in the USA due 
to the sourcing of the material from allogenic sources which 
may increase the chance of a negative immune response and 
rejection [12]. ACI has been shown to be effective through 
clinical trials which demonstrated positive functional and 
clinical outcomes in the early years following treatment and 
formation of hyaline-like tissue. This is potentially due to 
the use of autologous chondrocytes which have a greater 
inherent ability to form hyaline cartilage than MSCs. How-
ever, new tissue that is not morphologically or histochemical 
identical to normal hyaline cartilage and fibrocartilaginous 
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tissue was shown to develop in the majority of patients. This 
may be a result of the in vitro culturing stage as studies 
have demonstrated that chondrocytes dedifferentiate into 
fibro-chondrocytes in 2D culture, however, other studies 
have shown that by culturing the cells in a 3D and hypoxic 
environment this can be reversed [56, 57]. There are further 
limitations to ACI which include the need for two invasive 
surgical procedures combined with in vitro culturing and the 
subsequent long recovery period (6–12 months) needed to 
ensure successful neotissue formation.
A derivative of the ACI technique is matrix-induced 
autologous chondrocyte implantation (MACI), which can 
be considered as a tissue engineering approach as it utilises 
a scaffold to assist in cell attachment, distribution, and pro-
liferation, guiding new matrix formation. MACI is similar 
to ACI in that it requires the initial isolation of autologous 
chondrocytes from the patient and in vitro cell expansion, 
however, seeding is then carried out onto the scaffold, which 
can be made of collagen or hyaluronic acid. The cell-seeded 
scaffold is then cultured in vitro before implantation into 
the debrided defect and fixation with fibrin glue. The clini-
cal advantage of MACI over other techniques remains to be 
confirmed as current clinical trial data has shown that MACI 
either has similar or better functional results, thus is not 
widely utilised yet clinically. However, MACI has the same 
limitation as ACI due to the requirement of two surgical 
procedures. Furthermore, the tissue matures slowly and long 
recovery periods are required. However, the long recovery 
periods may happen with any treatment due to the nature of 
the limited regenerative capacity of articular cartilage. There 
are a number of benefits to using a scaffold based treatment 
such as easier fitting of the graft into the defect, improved 
graft stability, and better control in preventing dedifferentia-
tion of the chondrocytes due to fact that cells are cultured in 
a 3D matrix which reduces the formation of fibrocartilagi-
nous tissue [12, 58].
Alternatively, autologous matrix-induced chondrogenesis 
(AMIC) has been used to repair chondral and subchondral 
defects. This procedure is a single-step surgery that can 
be performed both arthroscopically or openly and consists 
of initial debridement of the defect, microfracture of the 
underlying bone to form a super clot, and the placement of 
a resorbable membrane to form a protected clot. The mem-
brane is sealed in place either with a fibrin glue or suturing. 
This protected blood clot provides a conducive environment 
for cartilage regeneration and the formation of hyaline-like 
cartilage. The membrane allows the entrapment of the blood 
clot, MSCs, and growth factors and is typically made from 
porcine-derived collagen I/III, however, hyaluronic acid 
and polyglycolic acid have also been utilised [80]. AMIC 
is advantageous compared to ACI and MACI as no in vitro 
cell expansion steps are required, no second surgical pro-
cedures is necessary, and there is no donor site morbidity. 
Randomised control trials show that AMIC using a collagen 
membrane had significant improvement and stability in clini-
cal results after five years compared to microfracture alone 
[81]. However, fibrocartilage formation was observed in his-
tological evaluation of two patient biopsies, indicating that 
chondrogenesis into a hyaline phenotype is restricted. Fur-
thermore, there is limited high-quality randomised control 
studies to provide evidence of the superiority of AMIC over 
typically used procedures such as microfracture and ACI 
thus further studies are required to assess its efficacy and 
clinical relevance in a range of joint defect conditions [82].
Finally, when considering the treatment of discrete carti-
lage defects, bone marrow aspirate concentrate (BMAC) has 
been recently explored to augment existing osteochondral 
repair techniques and can be used as a primary treatment 
option [83–86]. The bone marrow aspirate, typically derived 
from the iliac crest, contains a range of cellular components 
which are further isolated and concentrated, through density 
gradient centrifugation, to produce a BMAC which is rich 
in bone marrow derived MSCs, platelets, haematopoietic 
stem cells, and growth factors. This concentrated source of 
stem cells and growth factors can promote chondrogenic and 
osteogenic responses, migration and recruitment of cells, 
and vascularisation. Animal and human clinical trials have 
shown that the procedure is safe and has promising posi-
tive outcomes with improved cartilage repair. Although still 
inferior to hyaline cartilage tissue, BMAC enhances repair 
when used in conjunction with microfracture and matrix-
assisted procedures [83–85, 87–89]. What makes this 
technique agreeable to both surgeons and patients alike, is 
that it is simple and technically easy to perform as well as 
having minimal donor site morbidity compared with other 
techniques. However, currently no standard procedure for 
BMAC is available, thus, aspects of the concentrate such 
as cell and growth factor type and concentration will vary 
between individuals which will influence the quality of tis-
sue repair and clinical outcome.
Whole joint osteoarthritis represents a different clini-
cal challenge. Not only is the articular cartilage damaged, 
but the subchondral bone becomes deformed and the peri-
articular capsule, muscles and tendons become affected. 
Current treatment strategies are dominated by joint replace-
ment surgery [90]. Since the development of the success-
ful low friction arthroplasty by the late Sir John Charnley, 
the metal on high molecular weight polyethylene bearing 
surfaces have been widely used in total joint prostheses. In 
the UK over 160,000 hip and knee replacements are car-
ried out each year [91]. However, the challenge continues 
to overcome the mechanical loosening of these prostheses 
over time. In additional cellular regeneration strategies are 
unlikely to overcome the structural changes in all of the tis-
sues types that are involved [92]. Revision surgery to replace 
failed prostheses causes not only significant morbidity to the 
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patient but also the results of the second or subsequent joint 
replacement being significantly inferior to primary proce-
dures. There is an associated substantial financial burden to 
the healthcare system due to increased cost of peri-operative 
investigations, blood transfusions, surgical instrumentation, 
implants and operating time, as well as an increased length 
of stay in hospital which accounts for most of the actual 
costs associated with surgery. Prosthetic innovation has been 
able to reduce the incidence of implant failure by improving 
the techniques employed to ensure good integration with the 
host bone, e.g. coating implants with hydroxyapatite and 
using uncemented implants.
As previously described, current clinical techniques for 
cartilage repair are promising, however, positive clinical out-
comes rarely last more than 5 years and often gradually dete-
riorate over this period. None as of yet have fully repaired 
either an articular cartilage defect or a full osteochondral 
defect over the long-term. Furthermore, techniques such as 
ACI, MACI, and BMAC are limited to chondral defects only 
and are not suitable for osteochondral defects. However, as 
no other superior alternatives are available, these procedures 
continue to represent the mainstay of clinical management 
despite their failure to recreate hyaline cartilage. All the 
approaches described have significant limitations which not 
only fail to recapitulate the native structure and result in 
mechanical mismatch with failure over the long-term. Addi-
tionally, these techniques are associated with multiple proce-
dures, donor site morbidity, and long rehabilitation periods 
following treatment. Subsequently, long-term failure in these 
procedures can result in significant tissue degradation caus-
ing pain and limited mobility, thus potentially requiring a 
total joint replacement. New tissue engineering strategies 
are appealing as they might enable rapid weight bearing 
and fully integrated neotissue that subsequently develops 
into phenotypic and functional hyaline cartilage. These new 
clinical therapies are required to enhance the quality of life 
of patients and reduce the economic burden to healthcare 
systems.
Tissue engineering: requirements 
and strategies
Tissue engineering is a multidisciplinary field of research 
conducted to meet clear clinical requirements of therapies 
to promote the regeneration and repair of diseased and dam-
aged tissues. Tissue engineering approaches in cartilage 
regeneration and repair have great potential and provide an 
alternative to current available therapies which are inad-
equate, however, challenges remain [7, 9–12]. Engineered 
cartilage constructs are comprised of biomaterials, cells, 
and/or stimulatory factors (e.g. growth factors and bio-
mechanical stimulation), which are considered key to the 
design of functional cartilage tissue (Fig. 5) [93, 94]. Key 
cell sources explored for seeding of scaffolds or encapsula-
tion include chondrocytes [95], mesenchymal derived stem 
cells (e.g. bone, adipose, synovium) [7, 10, 96–98], induced 
pluripotent stem cells [99, 100], embryonic stem cells [101], 
and pericytes [102].
However, the current paradigm still lacks in the develop-
ment of long-term phenotypically stable articular cartilage 
tissue which exhibits integration with the surrounding tissue, 
mechanical stability, and withstands inflammatory factors, 
especially in a diseased environment such as osteoarthritis.
Biomaterials design and selection
Biomaterials are the backbone of 3D engineered constructs 
and support tissue growth and formation by providing a 
biomimetic environment to the native tissue and structural 
integrity during maturation to allow cell proliferation, cell to 
cell communication, and ECM formation. The ideal design 
specifications of 3D tissue engineered scaffolds from the 
biomaterials perspective include: (1) biocompatibility, cell 
viability with a desired cellular behaviour; (2) biodegra-
dability, the scaffold degrades at a controlled rate which 
matches tissue formation; (3) provides mechanical and bio-
chemical cues to promote a desired cellular response. An 
alternative strategy to the use of biomaterials is cell self-
assembly approaches such as spheroid formation which does 
not require supporting materials [103, 104].
Biomaterial scaffolds can be produced from different 
sources such as naturally derived polymers, synthetic poly-
mers, and ECM derived materials.
Naturally derived biopolymers have been explored exten-
sively for cartilage tissue engineering applications [11, 105, 
106]. The most associated advantages with naturally derived 
polymer is their capacity of supporting cell attachment, via-
bility, proliferation, attachment, and differentiation, and, in 
some cases, maintenance of cell phenotype [107]. This is 
mediated in protein derived biopolymers through binding 
motifs present in the polymer. Despite these key advantages, 
naturally derived polymeric materials present some draw-
backs such as poor degradation kinetics, limited processabil-
ity, and mechanical properties. However, these limitations 
may be improved through the modification of the polymer 
backbone or via crosslinking mechanisms [107]. For exam-
ple, gelatin is commonly modified by reaction with meth-
acrylic anhydride to form gelatin methacryloyl (GelMA) 
which contains both methacrylamide and methacrylate side 
groups [108–110]. This enables the formation of hydrogels 
via photo-mediated crosslinking in the presence of a pho-
toinitiator and the use of a suitable wavelength of light. This 
aids in biofabrication processes, especially in 3D bioprint-
ing, as the gel can be rapidly crosslinked after material depo-
sition or cell encapsulation. Furthermore, the mechanical 
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and morphological (e.g. porosity and pore size) properties 
of tissue constructs can be tuned by selecting the appropri-
ate reaction and crosslinking conditions. Additionally, the 
cell binding arginine-glycine-aspartic acid (RGD) motifs and 
matrix metalloproteinase (MMP) degradable sequences are 
retained within the modified gelatin, thus maintaining bio-
compatibility, and bioactivity, while allowing cell-material 
interaction and cell-mediated hydrogel degradation.
Naturally derived polymeric materials can be classified 
into two main categories:
1. Polysaccharides: gel forming polysaccharides such as 
alginic acid and mucopolysaccharides (glycosaminogly-
cans), storage polysaccharides which include starch and 
glycogen, and structural polysaccharides such as cellu-
lose and chitin.
2. Protein based polymeric material composed of amino 
acid groups such as collagen, gelatin, and silk fibroin. 
Proteins can be classified by their shape, size, solubility, 
composition, and function.
Synthetic polymers have shown potential in tissue engi-
neering due to their improved mechanical and degradation 
properties with the capacity to be more easily chemically 
modified or engineered to tune their properties [111–113]. 
The hydrolytic and enzymatic degradation of the polymer 
can be controlled through modification of the polymer [114]. 
However, due to lack of biologically functional domains, 
which can reduce the risk of immune response, synthetic 
polymers may not facilitate cell phenotype expression or 
cell attachment as occurs in naturally derived protein-based 
polymers. Several strategies have been pursued to tackle 
this limitation, including the blending with bioactive poly-
mers and the functionalisation of polymer backbone with 
cell-adhesive cues [115, 116]. Among synthetic polymers, 
PCL and poly(ethylene glycol) (PEG) have been the most 
extensively used to create mechanically robust 3D scaffolds 
with intricate geometries and 3D cell-laden hydrogels, 
respectively. PCL has been processed via melt extrusion and 
melt electrospinning to engineer acellular scaffolds which 
pores can be eventually filled with cell-laden hydrogels or 
cell spheroids towards creating biomimetic cartilage tis-
sue constructs [117–119] In turn, PEG functionalised with 
a variety of reactive groups has been explored to produce 
cell-instructive hydrogels with tuneable properties through 
several crosslinking chemistries, sustaining cartilage forma-
tion [115]. Recent works have explored dynamic covalent 
chemistries to engineer covalent adaptable networks with 
controllable viscoelasticity and stress relaxation, recreat-
ing such features of the native cartilage. As an example, 
Richardson et al. [120] cultured porcine chondrocytes within 
stress relaxing hydrazone crosslinked PEG and observed an 
Fig. 5  Tissue engineering strategies for articular cartilage regeneration. Image from [10]
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increased deposition of collagen (e.g., collagen type II) and 
sulfated glycosaminoglycans (e.g., aggrecan) in hydrogels 
exhibiting stress relaxation compared to predominantly elas-
tic hydrogels with slow average relaxation times. Results 
suggest that a fine control over the hydrogel viscoelasticity 
is essential to preserve gel network integrity, while support-
ing the formation of high-quality neocartilaginous tissue.
Decellularised extracellular matrix (dECM) based bioma-
terials have also been explored to create 3D constructs. The 
native ECM is ideal for tissue engineering as it is identical to 
the desired matrix structure required and helps controls cell 
behaviour [121–126]. Thus the use of dECM is suitable as 
it is biodegradable, does not produce antagonistic immune 
responses, provides cues for cell differentiation, and presents 
bioactive molecules that determine tissue homeostasis and 
tissue regeneration [121, 127, 128]. The replication of the 
ECM microenvironment has provided inspiration to use the 
ECM from articular cartilage as matrix for tissue regenera-
tion [127, 129]. Benders et al. demonstrated the fabrication 
of a decellularised cartilage tissue derived scaffold. This 
process comprises mechanical (grinding/milling of large 
tissue slices) and chemical (enzymatic and detergents) 
manipulation to remove the cellular components to allow 
formation into a scaffold structure which showed promis-
ing early-stage production of cartilage specific matrix [130, 
131]. Furthermore, bioinks based on dECMs have been 
developed offering an additional route for their use in tissue 
engineering applications [132–134]. The source of dECM, 
either derived from cartilage tissue or cellular has potentially 
an impact on cell behaviour with tissue-derived matrices 
showing greater chondrogenic differentiation whilst cellu-
lar-derived matrices facilitated enhanced cell proliferation 
and chondrogenic potential, although further investigation 
is required to understand the discrepancies [121]. Decellu-
larisation protocols from harvesting, decellularisation, and 
sterilisation to creating the dECM based scaffolds affects 
the hydration status and 3D configuration of the proteins 
and ECM, and hence strongly influences biomechanical and 
biological behaviour properties which may not be suitable 
anymore [122, 135]. Furthermore, concerns remain about 
potential immunogenicity and poor biomechanical and bio-
logical performance.
The selection of suitable biomaterials, biofunctionalisa-
tion strategies and processing technologies are essential to 
engineer a cell- and tissue-specific environment that pro-
motes desirable cell behaviour and functional tissue forma-
tion (Fig. 6). Each class of biomaterials has their own advan-
tages and disadvantages, thus, there is difficulty in selecting 
only a specific class of biomaterial for use in osteochondral 
tissue engineering. Despite the limited long-term evidence 
of clinical outcomes currently, many ongoing trials and 
early-stage outcomes are positive and report encouraging 
results [10, 13]. Subsequently, the development of advanced 
hydrogels which can combine the advantages of both syn-
thetic and natural polymers, for example, in hybrid systems 
and synthetic self-assembling peptides are promising solu-
tions [136, 137].
Bioprinting cartilage tissue
The advancement of 3D printing and 3D bioprinting in tis-
sue engineering has allowed the fabrication of scaffolds and 
biological tissue models that more accurately reflect the 
complex organisational structure and material properties of 
tissues and organs [14, 139]. 3D bioprinting uses biomateri-
als, cells (encapsulated or seeded), and biomolecules, typi-
cally referred to as a bioink, which are precisely deposited 
in a layer-by-layer process to build-up a 3D structure. The 
ability to print multiple cells and biocompatible materials 
with greater design freedom compared with conventional 
fabrication techniques has enabled the development of 3D 
structures that resemble the complex 3D biophysical and 
biochemical environment in tissues. The use of 3D bioprint-
ing within cartilage tissue engineering is becoming wide-
spread as an enabler technology to fabricate complex multi-
material structures that mimic, in some extent, the biological 
and mechanical properties of cartilage tissue [15, 140]. Cur-
rently, 3D bioprinting predominately uses inkjet, extrusion, 
and laser-assisted systems to fabricate 3D structures (Fig. 7). 
However, stereolithography based systems are gaining atten-
tion due to the development of novel visible light photoini-
tiators with improved cytocompatibility and advancements 
in the technology which promises faster fabrication times 
and increased structure complexity [141–143].
The development of bioinks has become an essential 
factor for the success of 3D bioprinting, in particular, 
biomaterials with controllable mechanical, biological, 
and biophysical characteristics which can modulate cell 
behaviour combined with printability (Fig. 8) [17, 145, 
146]. Printing resolution, structure fidelity, material vis-
coelasticity are crucial parameters in determining the 
printability of bioinks and its relationship to the final 
mechanical and biological properties of the structure. 
Developing advanced bioinks requires consideration of 
pre-functionalisation processes to incorporate biological 
functional groups and crosslinking moieties, the rheologi-
cal behaviour of the bioink to ensure printability and fidel-
ity, and the crosslinking method to ensure rapid gelation of 
the hydrogel [147–150]. More importantly, such require-
ments must also have in consideration that cell behaviour 
and functional properties of the new tissue depend not only 
on the bioprinting parameters (e.g., shear stress, crosslink-
ing conditions), but also on the cell microenvironment 
provided by the engineered materials [151]. Depending 
on the biofabrication process and material properties, the 
bioink polymers will have various chemical and physical 
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characteristics that will determine the corresponding 
application [152]. These properties can be determined 
by rheological characterisation, mechanical assessment 
and crosslinking properties of the hydrogel [152, 153]. 
Shear-thinning behaviour, a decrease in the viscosity as a 
function of increasing shear rate, is crucial for bioprinting 
applications, since the material will flow with an applied 
force during printing and the lower the applied force the 
higher the cell viability [16, 150, 154]. The viscoelastic 
behaviour characterised by the material response during 
printing needs to be optimised as low viscous materials 
will deform and collapse during printing, unless a rapid 
crosslinking process can be initiated. On the contrary high 
viscosity materials can be difficult to print as they can 
Fig. 6  Engineering biomimetic materials to generate tissue-specific 
microenvironments. a Natural and synthetic hydrogels can be engi-
neered to contain peptides and proteins (e.g. cell binding sites and 
growth factors). b The hydrogels can mimic the native extracellular 
matrix through incorporation of cell-sensitive degradable crosslinks 
and proteins. c Biomechanical properties of the hydrogel can be regu-
lated by exploring different chemistries allowing to independently 
tune the crosslinking density. d Native extracellular matrix in tissues 
and organs can have their cells removed through a decellularisation 
process to produce scaffolds with different forms such as particles, 
tubes, and sheets. e Cell migration and recruitment into functional-
ised biomaterials can be further explored to modulate their behaviour 
and enhance regenerative responses. Image from [138]
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block the printing nozzle, require high deposition force, 
and restrict cell attachment and spreading which can nega-
tively impact cell viability [155, 156].
Multiple bioprinting-based strategies have been pro-
posed to generate hierarchical tissue constructs for car-
tilage applications. One of the early proposed strategies 
involved the extrusion bioprinting of cell-laden hydrogel 
bioinks to directly produce 3D cellularised constructs 
stimulating cartilage formation [158]. Despite promising 
outcomes, a major drawback of hydrogel constructs relies 
on the disparity of mechanical properties compared to the 
native cartilage. To overcome this issue, researchers have 
combined melt extrusion or melt-electrospinning writing 
of thermoplastic polymers such as PCL with extrusion bio-
printing of cell-laden hydrogel bioinks towards the fabri-
cation of reinforced 3D constructs with improved mechan-
ical performance (Fig. 9). This concept was explored by 
Visser et al. [118], who reinforced chondrocyte-loaded 
hydrogels with direct writing of melt-electrospun PCL 
microfibres achieving up to 54-fold increase in the stiffness 
of composite constructs when compared with the hydro-
gel alone constructs. A similar approach was reported by 
Kang et al. [159] using an integrated tissue–organ printer 
(ITOP) to generate 3D constructs for cartilage reconstruc-
tion via the sequential melt extrusion of PCL strands and 
the extrusion bioprinting of chondrocyte-laden hydro-
gels. In another study, Mekhileri et al. [119] proposed 
a hybrid biofabrication approach combining alternating 
melt extrusion of a thermoplastic polymer (poly(ethylene 
glycol)-terephthalate-poly(butylene terephthalate) block 
copolymers) and microfluidic bioassembly of pre-formed 
cellular spheroid modules to create hierarchical constructs 
for cartilage tissue engineering. These examples clearly 
illustrate that the synergy between different biofabrication 
technologies holds tremendous promising in create truly 
biomimetic 3D constructs able to surpass the limitations 
of individual technologies/strategies. 
Fig. 7  3D bioprinting technolo-
gies commonly used in tissue 





















Fig. 8  Bioink properties for 
successful 3D bioprinting 
require a suitable, a biofabrica-
tion window which balances 
printability and biocompatibility 
whilst providing a variety of (b) 
suitable rheological, mechani-
cal, and biological characteris-
tics. Image from [157]
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Biochemical and biomechanical stimulation
Biochemical, biophysical, and biomechanical stimulation 
of 3D bioengineered constructs is crucial in the formation 
and maturation of functional neocartilage tissue (Fig. 10). 
The stimulation of cells can be achieved at specific stages: 
cell expansion, differentiation, and the maturation of the 
tissue construct in vitro. This can be attained through sup-
plementation of the cell culture media, incorporation of 
biomolecules within the 3D structure, engineering the bio-
physical ECM environment, and mechanical stimulation 
of the construct.
A key approach to direct cell behaviour and facilitation of 
neocartilage tissue formation is the use of biological signal-
ling molecules (e.g. growth and transcription factors) dur-
ing cell culture, tissue maturation, and utilisation via direct 
inclusion, encapsulation or binding to the biomaterial matrix 
of the construct [10, 160–164]. A range of growth and 
transcription factors have been identified and investigated 
including transforming growth factors (TGFs), bone mor-
phogenetic proteins (BMPs), insulin growth factors (IGFs), 
fibroblastic growth factors (FGFs), platelet-derived growth 
factors (PDGFs), and sex determining region Y (SRY)-box 
(SOXs).
Growth factors are proteins that have a key role in cell 
behaviour and regulate cellular growth, proliferation, differ-
entiation, and migration and are grouped into families with 
shared amino acid sequences and superfamilies with shared 
structural folds [161, 162].
In articular cartilage tissue engineering, 3D engineered 
constructs have been used to deliver these biological factors 
[162, 165]. For instance, TGF-β1 stimulates the synthesis 
of cartilage ECM, maintenance of chondrocyte phenotype, 
synthesis of proteoglycans, aggrecan and type II collagen 
and can enhance the repair of cartilage defects [166, 167]. 
IGF-1 has been reported showing high anabolic effects and 
decrease in catabolic responses in articular cartilage metabo-
lism in vitro [167, 168]. Other studies have reported using 
different growth factors which were successful in produc-
ing several features that resembled typical articular cartilage 
[169–171]. Despite the capacity to promote cartilage matrix 
formation, growth factors have shown some drawbacks with 
IGF-1 associated with a loss of chondrocyte phenotype and 
extracellular matrix breakdown [168]. Furthermore, IGF-1 
in human MSCs inhibited collagen II expression and over-
expression can induce hypertrophic differentiation and min-
eralisation [172].
Biomechanical stimulation is a key factor in the devel-
opment and homeostasis of functional cartilage tissue 
[173–177]. The importance of mechanical loading and 
physical movement on embryonic chondrogenesis has been 
demonstrated in chicken embryos which when physically 
impaired exhibited poor development of cartilage tissue 
[178–180]. Mechanical loading is required for healthy tis-
sue, however, excessive loading can lead to trauma and 
disease progression [173]. Thus, mechanical stimulation 
of cells and tissue constructs via compression, shear and 
hydrostatic pressure is important to promote chondrogenic 
differentiation, maintain a chondrogenic phenotype, and gen-
eration of functional tissue in vivo. Mechanical stimulation 
of MSCs under varied loading regimes have been shown to 
increase the deposition and expression of collagen II, aggre-
can, GAG, TGF-β1/β3, and SOX9 and modulated secretory 
factors such as stromal‐derived factor‐1 (SDF-1), matrix 
metalloproteinase‐2 (MMP-2), TGF-β1/β3, FGF, vascular 
endothelial growth factor (VEGF), activated leukocyte cell 
adhesion molecule (ALCAM), nitric oxide, urokinase recep-
tor (uPAR), macrophage inflammatory protein 3α (MIP3α). 
The advancement of bioreactors in tissue engineering has 
enabled the use of mechanical stimulation as a key capability 
in engineering cartilage tissue formation [181–183]. Dual 
compressive and shear mechanical stimulation of human 
articular chondrocytes encapsulated in gelatin methacrylate 
and hyaluronic acid methacrylate hydrogels have been dem-
onstrated by Meinert et al. [184]. Cartilage specific marker 
genes and ECM were upregulated with significant increases 
in collagen II synthesis. Combining compressive and shear 
stimulation has been investigated using a multi-axial loading 
bioreactor which mimics the movement of an articulating 
joint [185, 186]. Vainieri et al. investigated a chondrocyte 
Fig. 9  Bioprinting hybrid cell-laden scaffolds. (1) Hydrogels rein-
forced with direct writing of melt-electrospun microfibres. L: a 
Schematic of the melt-electrospinning system. b, c Fibre deposi-
tion and spacing can be precisely controlled (scale = 1  mm) with 
d fused fibres at the cross-sections (scale = 200  µm) and e highly 
porous structures fabricated. M: a Microfibres reinforce the hydro-
gel during axial compression and stretch with lateral displacement 
(scale = 1  mm) enabling a similar, b stiffness to articular cartilage 
tissue. R: Chondrocytes encapsulated in a unreinforced and b rein-
forced hydrogels (scale bar = 2 mm) demonstrate, c rounded morphol-
ogy (scale = 500  µm, inlay 200  µm, and d homogenous distribution 
(scale = 200  µm). Images adapted from [118]. (2) Integrated tissue–
organ printer. L: a Schematic of the multi-printhead 3D bioprinting 
system and b the basic patterning of cell-laden hydrogels and sup-
porting thermoplastic polymers. c Design and biofabrication process 
of the system. R: a 3D bioprinting of cell-laden hydrogels and PCL 
with integrated microchannels. a Gross appearance, b histological 
staining, and c GAG production after 1- and 2-month in vivo implan-
tation. d Bending mechanics and stress–strain curves, e before and 
f after 1-month implantation. Images adapted from [159]. (3) Auto-
mated 3D microfluidic bioassembly of cellular spheroids and hybrid 
constructs. L: a Representation of the 3D bioprinting and bioas-
sembly system. b Two-step bottom-up strategy involving 3D print-
ing a scaffold and subsequently injecting microtissues whilst a (c) 
multi-step process uses an alternating layer-by-layer process. R(top): 
a Computer-aided-design model and b example of a hybrid bipha-
sic osteochondral construct. R(bottom): a–f Bioassembled micro-
tissues and g, h micro-spheres demonstrate chondrogenic markers 
(a–c: safranin-O, d–f: collagen II, and h: aggrecan) and cell viability. 
Images from [119]
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seeded hybrid fibrin-polyurethane scaffold implanted in a 
osteochondral defect model that was mechanically stimu-
lated using a joint mimicking bioreactor [186]. The results 
showed increased production of chondrogenic specific mark-
ers, proteoglycan 4 and cartilage oligomeric matrix protein, 
and the improved collagen II to I ratio. Alternatively, tensile 
stimulation of a self-assembled scaffold-free neocartilage 
construct has shown to increase the tensile strength and 
modulus of the construct and once implanted in vivo in a 
mice model had similar mechanical properties and collagen 
content of native tissue [187]. The development of improved 
mechanically stimulating bioreactors and osteochondral 
models will provide a valuable tool in understanding carti-
lage development and will aid the screening of biomaterials 
and tissue engineering strategies.
Challenges and future perspectives
Major barriers remain in the development of clinically effec-
tive therapies for articular cartilage and osteochondral tis-
sue. These challenges stem for the complexity of the native 
tissue and the difficulty in guiding regenerative processes 
while halting degenerative pathologies. This section briefly 
summarises key challenges identified associated with stimu-
latory factors, tissue inflammation, and implant-native tissue 
integration.
Challenges remain in the use of stimulatory processes to 
guide cell behaviour and tissue development. A complete 
understanding of chondrogenic development is still being 
unravelled so the entire milieu of factors that influence tissue 
formation and their functional spatiotemporal presentation to 
the cells is incomplete. However, tissue engineering strate-
gies will most likely, to be successful, use a combination of 
growth factors, a controlled biophysical environment, and 
mechanical stimulation to promote tissue formation with 
phenotypic stability. This is supported by the fact that the 
use of stem cells and chondrocytes, derived or implanted 
into an osteoarthritic environment, in vitro or in vivo typi-
cally results in phenotypic instability and the expression of a 
hypertrophic chondrocyte phenotype [66, 188, 189]. Biomol-
ecules which can inhibit hypertrophic differentiation have 
been identified such as parathyroid hormone related peptide, 
BMP-7, SOX-5/6/9, and Nkx3.2 (transcription factor) thus 
potentially providing a route to address this issue [190–194]. 
However, the osteoarthritic joint environment, a main clini-
cal target, presents an obstacle as the disease itself presents a 
Fig. 10  Biochemical and biomechanical stimulation combined with appropriate cell sources can be used to engineer cartilage tissue constructs. 
Image from [160]
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degraded and complex growth factor/cytokine environment. 
This can contribute to induce a hypertrophic phenotype in 
chondrocytes which may have significant implications for 
the development of functional implanted tissue constructs 
[66, 189]. This will require further understanding of the 
specific disease state and how different states affect the suc-
cess of the tissue engineering approach used. The sole use 
of soluble factors in the maintenance and differentiation of 
chondrocytes and MSCs in vitro and in vivo seems unlikely 
to achieve the desired results. Rather the design of these 
stimulatory environments including biochemical, physical, 
and mechanical elements will aim to recapitulate the native 
environment during all developmental stages of the tissue. 
A successful strategy will need to determine the combina-
tion, dosage, and delivery profile of growth factors, as well 
as the design of the physical matrix surrounding the cells by 
controlling parameters such as crosslinking density, ECM 
protein selection, and oxygen tension. Finally, determin-
ing the timing, type, and loading conditions of mechanical 
stimulation will be essential in promoting an ECM which 
is mechanically compliant. However, the complexity of 
this environment and the actual implementation of a multi-
stimulatory strategy is a serious challenge for researchers.
The considerable inflammatory environment of osteo-
chondral tissue in a diseased (e.g. osteoarthritis and rheuma-
toid arthritis) or trauma state presents a significant obstacle 
for successful clinical outcomes of tissue engineered con-
structs, hindering tissue-construct integration and tissue 
regeneration (Fig. 11a) [69, 195–201]. Thus, approaches 
are necessary to control and understand the inflammatory 
state which contributes to tissue degradation in osteoarthritic 
diseases and the influence on implanted tissue constructs. 
Pro-inflammatory cytokines (e.g. interleukin-1β/-6 and 
tumour necrosis factor-α) have been implicated in the devel-
opment of cartilage degradation in osteoarthritic joints and 
activation of the nuclear factor kappa B pathway; which can 
also contribute to the inhibition of chondrogenesis in human 
MSCs [195, 197, 198, 200–203]. Subsequently, understand-
ing and modulating the inflammatory environment is key 
and has been investigated through a range of approaches 
including co-cultured adipose-derived MSCs [204], growth 
factors [165, 195, 196], platelet-rich plasma [205–208], 
control of macrophage phenotype [209–211], inhibition of 
anti‐chondrogenic factors [212], and inflammation modulat-
ing biomaterials [213, 214].
Integration of tissue constructs with the surrounding 
native tissue, be that cartilage or subchondral bone, is a key 
challenge. The issue of integration is a complex problem 
and can be caused be factors including lack of vascularisa-
tion, cell donor age, cell death during surgery and construct 
implantation, cell phenotype, and stage of tissue maturation 
of the construct [215]. This is further compounded by the 
anti-adhesive properties of proteoglycans and GAGs present 
in the native matrix which are essential for proper function-
ing but can prevent integration. To overcome this issue, 
enzymatic degradation (e.g. trypsin and chondroitinase-
ABC) of the tissue interface has been explored to temporar-
ily reduce proteoglycan and GAG content to facilitate tissue 
integration (Fig. 11b) [216–219]. Furthermore, the native 
ECM can impede diffusion of proteins and cells, thus, dis-
rupting the ECM at the site of implantation by using col-
lagenase and hyaluronidase can enhance cell density and 
Fig. 11  a Complex pro-inflammatory cytokine environment in osteo-
arthritis leads to upregulation of catabolic and downregulation of ana-
bolic processes resulting in tissue degradation. Cartilage degradation 
products and pro-inflammatory signals act on the synovium inducing 
further inflammatory processes that enhances the deregulation of typ-
ical chondrocyte function. Image from [200]. b Strategy to enhance 
implant integration with native cartilage tissue using a combination 
of chondroitinase-ABC, TGF-β1, and collagen crosslinking enzyme 
LOX. Image from [219].
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integration [220]. Collagen crosslinking between the native 
cartilage and tissue construct can be encouraged by mini-
mising complete crosslinking of the construct by blocking 
the enzyme lysyl oxidase (LOX) subsequently increasing 
the availability of collagen precursor crosslinking sites to 
enhance integration. Correspondingly, the construct-native 
tissue interface can be treated with LOX to enhance and 
mature collagen crosslinking via collagen pyridinoline 
crosslinks that can anchor and bridge the interface [219, 
221]. However, implant integration can be influenced by the 
post-surgery recovery plan, thus appropriate rehabilitation 
regimes need to be followed. Furthermore, development of 
surgical procedures to secure implants in place during the 
integration and maturation phase are required. For example, 
Vapniarsky et al. have demonstrated a new technique which 
does not require suturing of the implant [222].
Concluding remarks
The clinical size and market of cartilage and osteochondral 
problems is expanding due to the ageing worldwide popula-
tion and the most common treatment approaches are ineffec-
tive at halting the progression of degeneration of the tissue 
[65, 66, 69]. Thus, tissue engineering strategies are key in 
solving this pressing clinical problem. The design specifi-
cation of any biomaterial-based 3D construct must fulfil a 
stringent criterion requiring suitable biomaterial selection, 
scaffold architecture, fabrication technique, stimulatory fac-
tors, and tissue maturation.
Key areas of research include the maintenance of pheno-
type in the engineered tissue construct and the prevention of 
hypertrophic or fibrocartilage phenotypes being expressed. 
Expansion of therapeutic cells in vitro to sufficient quanti-
ties for clinical applications whilst maintaining cell pheno-
type is a key challenge and research goal. The number of 
autologous chondrocytes that can be harvested is limited and 
subsequent passaging rapidly induces phenotypic changes. 
Thus, the development of in vitro culturing processes that 
maintain chondrocyte phenotype and guide chondrogenic 
development of alternative cell sources. Allogenic cells are 
an attractive source as articular cartilage is typically con-
sidered immune-privileged due to its avascular nature thus 
allowing the use of allografts. However, this is dependent 
on implant location within the joint and proximity to the 
synovium consequently this needs to be taken into consid-
eration when developing tissue engineering therapies [223].
Another important issue concerns to the development of 
more effective strategies to promote the integration of tissue 
constructs with the host healthy tissue in an osteochondral 
defect, although in total replacement the strategy would pri-
marily to be to anchor the neocartilage to underlying bone. 
Furthermore, the underlying biological behaviour of the 
tissue, the early-stage developmental biology, haemostatic 
processes in adult tissue, and the inflammatory environment 
in osteoarthritic joints need further understanding.
This knowledge may unlock key aspects of the tissue 
which may guide tissue engineering strategies. This could 
require a strategy of multiple stimulatory factors (e.g. 
growth factors and mechanical stimulation) over an extended 
maturation time of up to many years to mimic the underly-
ing biological development of the tissue and even then, the 
incorporation of permanent mechanical structures may be 
necessary. Subsequently, future studies should focus on a 
multi-stimulatory environment, long-term studies to deter-
mine phenotypic alterations and tissue formation, and the 
development of novel bioreactor systems that can more accu-
rately resemble the in vivo environment. Furthermore, novel 
approaches utilising gene therapy combined with tissue 
engineering scaffolds are also a promising approach which 
may offer a route to solving intractable issues surrounding 
articular cartilage degeneration [224, 225]. Finally, a clear 
and considered route in the development process of the 
materials, structures, and strategy should be evaluated prior 
and during the research phase to expediate clinical and regu-
latory approval. This will allow faster and more successful 
access to animal trials and eventually human clinical trials 
with the prospect of an efficacious therapy being developed.
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